HeartBeam to Attend JP Morgan 2025 Annual Healthcare Conference
HeartBeam (NASDAQ: BEAT) announced its participation in the JP Morgan 2025 Annual Healthcare Conference, scheduled for January 13-16, 2025, in San Francisco. The company's leadership will be available for meetings to discuss their recently FDA-cleared HeartBeam system for comprehensive arrhythmia assessment.
The breakthrough device, the first of its kind to receive FDA clearance, features a credit card-sized form factor and cable-free design. It uniquely captures ECG signals from three distinct directions, providing actionable heart health information. The company plans to implement an Early Access Program and aims to leverage AI technology to analyze longitudinal ECG data, potentially predicting cardiac conditions before symptom onset.
HeartBeam (NASDAQ: BEAT) ha annunciato la sua partecipazione alla Conferenza Annuale sulla Salute JP Morgan 2025, programmata per il 13-16 gennaio 2025, a San Francisco. I leader dell'azienda saranno disponibili per incontri per discutere del loro recentemente approvato dalla FDA HeartBeam system per la valutazione completa delle aritmie.
Il dispositivo innovativo, il primo del suo genere ad ottenere l'approvazione della FDA, presenta un formato delle dimensioni di una carta di credito e un design senza cavi. Cattura in modo unico i segnali ECG da tre direzioni distinte, fornendo informazioni utili sulla salute del cuore. L'azienda prevede di implementare un Programma di Accesso Anticipato e mira a sfruttare la tecnologia AI per analizzare i dati ECG longitudinali, potenzialmente prevedendo condizioni cardiache prima della comparsa dei sintomi.
HeartBeam (NASDAQ: BEAT) anunció su participación en la Conferencia Anual de Salud de JP Morgan 2025, programada para el 13-16 de enero de 2025, en San Francisco. El liderazgo de la compañía estará disponible para reuniones para discutir su recientemente aprobado por la FDA sistema HeartBeam para la evaluación integral de arritmias.
Este dispositivo innovador, el primero de su tipo en recibir la aprobación de la FDA, cuenta con un tamaño similar al de una tarjeta de crédito y un diseño sin cables. Captura de manera única las señales de ECG desde tres direcciones distintas, proporcionando información útil sobre la salud del corazón. La empresa planea implementar un Programa de Acceso Anticipado y aspira a aprovechar la tecnología de IA para analizar datos de ECG longitudinales, potencialmente prediciendo condiciones cardíacas antes de la aparición de síntomas.
HeartBeam (NASDAQ: BEAT)는 2025년 1월 13일부터 16일까지 샌프란시스코에서 열리는 JP Morgan 연례 의료 회의에 참여한다고 발표했습니다. 회사의 리더십은 최근 FDA 승인을 받은 종합 부정맥 평가를 위한 HeartBeam 시스템에 대해 논의하기 위해 미팅을 가질 예정입니다.
이 혁신적인 장치는 FDA 승인을 받은 최초의 유사한 제품으로, 신용 카드 크기와 케이블 없는 디자인을 특징으로 합니다. ECG 신호를 세 가지 독립적인 방향에서 독특하게 캡처하여 심장 건강에 관한 실행 가능한 정보를 제공합니다. 회사는 조기 접근 프로그램을 구현할 계획이며, AI 기술를 활용하여 장기적인 ECG 데이터를 분석하고 증상이 나타나기 전에 심장 질환을 예측하는 것을 목표로 하고 있습니다.
HeartBeam (NASDAQ: BEAT) a annoncé sa participation à la Conférence Annuelle sur la Santé de JP Morgan 2025, prévue du 13 au 16 janvier 2025 à San Francisco. La direction de l'entreprise sera disponible pour des réunions afin de discuter de leur système HeartBeam pour l'évaluation complète des arythmies récemment approuvé par la FDA.
Ce dispositif révolutionnaire, le premier de son genre à obtenir l'approbation de la FDA, présente un format de la taille d'une carte de crédit et un design sans câble. Il capture de manière unique les signaux ECG sous trois angles différents, fournissant des informations exploitables sur la santé cardiaque. L'entreprise prévoit de mettre en place un Programme d'Accès Anticipé et a l'intention de tirer parti de la technologie IA pour analyser les données ECG longitudinales, prédisant potentiellement des conditions cardiaques avant l'apparition des symptômes.
HeartBeam (NASDAQ: BEAT) gab bekannt, dass sie an der JP Morgan Jahrestagung für Gesundheitswesen 2025 teilnehmen werden, die vom 13. bis 16. Januar 2025 in San Francisco stattfindet. Die Führungskräfte des Unternehmens werden für Meetings zur Verfügung stehen, um über ihr kürzlich von der FDA genehmigtes HeartBeam-System zur umfassenden Beurteilung von Arrhythmien zu diskutieren.
Das wegweisende Gerät, das erste seiner Art mit FDA-Zulassung, hat ein kreditkartengroßes Format und ein kabelloses Design. Es erfasst auf einzigartige Weise ECG-Signale aus drei verschiedenen Richtungen und liefert umsetzbare Informationen zur Herzgesundheit. Das Unternehmen plant die Implementierung eines frühen Zugangsprogramms und beabsichtigt, AI-Technologie zu nutzen, um longitudinale ECG-Daten zu analysieren und potenziell Herzkrankheiten vor dem Auftreten von Symptomen vorherzusagen.
- None.
- None.
- HeartBeam system was recently cleared by US Food and Drug Administration (FDA) for comprehensive arrhythmia assessment
- The Company is gearing up for an Early Access Program to gain initial commercialization learnings
HeartBeam Chief Executive Officer, Robert Eno, and Chief Financial Officer, Timothy Cruickshank, will be available January 13-15 for off-site meetings with investors and potential commercialization and co-development partners to discuss the Company’s recently announced US Food and Drug Administration (FDA) 510(k) clearance of the HeartBeam system for comprehensive arrhythmia assessment. With its patented design, the HeartBeam device is the first-of-its-kind to receive FDA clearance. As a high-fidelity electrocardiogram (ECG) system with a credit card-sized form factor and cable-free design, it captures heart signals from three distinct directions for actionable heart health information.
HeartBeam's proprietary technology has the potential to unlock valuable diagnostic and predictive insights. The ease of collecting higher-fidelity ECG signals will enable patients to gather a series of recordings over time. The Company aims to leverage AI to analyze this rich set of data, delivering a longitudinal view of a patient’s cardiac health and predicting cardiac conditions before symptoms appear. HeartBeam believes its groundbreaking technology presents a transformative opportunity to bring about a paradigm shift in cardiovascular care for millions of patients globally.
To schedule an off-site one-on-one meeting with HeartBeam management during the event, please contact MZ Group at BEAT@mzgroup.us.
About HeartBeam, Inc.
HeartBeam, Inc. (NASDAQ: BEAT) is a medical technology company dedicated to transforming the detection and monitoring of critical cardiac conditions. The Company is creating the first ever cable-free synthesized 12-lead ECG capable of capturing the heart’s electrical signals from three distinct directions. This platform technology is designed for portable devices that can be used wherever the patient is to deliver actionable heart intelligence. Physicians will be able to identify cardiac health trends and acute conditions and direct patients to the appropriate care – all outside of a medical facility, thus redefining the future of cardiac health management. The Company holds 13 US and 4 international issued patents related to technology enablement. For additional information, visit HeartBeam.com.
About the HeartBeam System
The HeartBeam System is a portable non-invasive recorder intended to record, store, and transfer a patient’s 3-Lead (in three-directions) electrocardiogram (ECG) acquired from 5 electrodes. The device is intended to be used by adult patients in either a clinical setting or at home. The device does not conduct cardiac analysis and can be used with an ECG Viewer software system for manual interpretation of non-life-threatening arrhythmias by a physician or healthcare professional. For full safety information, see the full Instructions for Use or Clinician Portal Manual.
Forward-Looking Statements
All statements in this release that are not based on historical fact are "forward-looking statements." While management has based any forward-looking statements included in this release on its current expectations, the information on which such expectations were based may change. Forward-looking statements involve inherent risks and uncertainties which could cause actual results to differ materially from those in the forward-looking statements, as a result of various factors including those risks and uncertainties described in the Risk Factors and in Management’s Discussion and Analysis of Financial Condition and Results of Operations sections of our Forms 10-K, 10-Q and other reports filed with the SEC and available at www.sec.gov. We urge you to consider those risks and uncertainties in evaluating our forward-looking statements. We caution readers not to place undue reliance upon any such forward-looking statements, which speak only as of the date made. Except as otherwise required by the federal securities laws, we disclaim any obligation or undertaking to publicly release any updates or revisions to any forward-looking statement contained herein (or elsewhere) to reflect any change in our expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241222771475/en/
Investor Relations Contact:
Chris Tyson
Executive Vice President
MZ North America
Direct: 949-491-8235
BEAT@mzgroup.us
www.mzgroup.us
Media Contact:
media@heartbeam.com
Source: HeartBeam, Inc.
FAQ
What is unique about HeartBeam's (BEAT) newly FDA-cleared cardiac device?
When is HeartBeam (BEAT) attending the JP Morgan Healthcare Conference 2025?
How does HeartBeam (BEAT) plan to implement AI in their cardiac monitoring system?
What is HeartBeam's (BEAT) Early Access Program for their cardiac device?
What type of cardiac data does HeartBeam's (BEAT) device collect?
